Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer.

Life science alliance - 1 Sept 2021

McAndrews Kathleen M, Xiao Fei, Chronopoulos Antonios, LeBleu Valerie S, Kugeratski Fernanda G, Kalluri Raghu

Abstract excerpt

CRISPR/Cas9 is a promising technology for gene editing. To date, intracellular delivery vehicles for CRISPR/Cas9 are limited by issues of immunogenicity, restricted packaging capacity, and low tolerance. Here, we report an alternative, nonviral delivery system for CRISPR/Cas9 based on engineered exosomes. We show that non-autologous exosomes can encapsulate CRISPR/Cas9 plasmid DNA via commonly available...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allografts
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exosomes

Share to Gene Editing

Share to Gene Targeting

Share to Gene Transfer Techniques

Share to MAP Kinase Signaling System

Share to Oncogenes

Source

Open in PubMed Open full text

Identifiers

PMID: 34282051
DOI: 10.26508/lsa.202000875
PMCID: PMC8321670

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer.PMID 34282051Read ↗

CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlookSemantic proximity Read ↗

Precision Oncology in the CRISPR Era: Applications and Future Horizons in Cancer TherapySemantic proximity Read ↗

Precision Oncology in the CRISPR Era: Applications and Future Horizons in Cancer TherapySemantic proximity Read ↗

An exosome-based gene delivery platform for cell-specific CRISPR/Cas9 genome editingSemantic proximity Read ↗

Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer.Semantic proximity Read ↗

A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivoSemantic proximity Read ↗

Efficacy of CRISPR-Cas9 Gene Editing for Targeting KRAS Mutations in Pancreatic Cancer: A systematic reviewSemantic proximity Read ↗

Packaging and Uncoating of CRISPR/Cas Ribonucleoproteins for Efficient Gene Editing with Viral and Non-viral Extracellular NanoparticlesSemantic proximity Read ↗

CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines.Semantic proximity Read ↗

Exosomes in Precision Oncology: From Bench to Bedside in Diagnostics and TherapeuticsSemantic proximity Read ↗

Mutant KRAS is a druggable target for pancreatic cancer.Semantic proximity Read ↗

KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.